Clinical Trials Browser

Has announcements × Carcinoma, Non-Small-Cell Lung × Cisplatin × Clear all

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3 Active not recruiting

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Phase 3 Completed

376 enrolled 34 charts 1 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03425643 2024-12-03

MK-3475-671

Phase 3 Active not recruiting

797 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02578680 2024-09-20

MK-3475-189

Phase 3 Completed

616 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Phase 3 Completed

345 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung